HRT Black Box Warning: What the 2026 FDA Label Change Means for Women

The HRT black box warning has not disappeared, but it is now much narrower. On November 10, 2025, the U.S. Food and Drug Administration (FDA) asked manufacturers to remove the boxed-warning language about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy (MHT, usually called HRT) labels. On February 12, 2026, the agency approved the first six updated labels. One boxed warning stays: the risk of endometrial cancer (cancer of the uterine lining) with systemic estrogen-alone products in women who still have a uterus. Heart and breast cancer risks remain in the label too. They have moved from the box into the Warnings and Precautions section for systemic products. As of October 2026, the FDA’s list of updated labels still names only six products, so many prescriptions may still carry the older wording. One thing has not changed: HRT still requires a medical evaluation, a diagnosis and ongoing supervision by a licensed clinician.

Key Takeaways

• The FDA requested the label changes on November 10, 2025, and approved the first six updated labels on February 12, 2026. In total, 29 drug companies have submitted proposed changes at the FDA’s request.
• The boxed warning no longer covers cardiovascular disease, breast cancer or probable dementia. The dementia warning is gone from the labeling entirely, and the advice to use “the lowest effective dose for the shortest duration” has been dropped from the box.
• The estrogen black box warning for endometrial cancer stays on systemic estrogen-alone products, because estrogen without a progestogen can thicken the uterine lining.
• The average participant in the Women’s Health Initiative (WHI), the study behind the 2003 warning, was 63 years old. The average age at menopause in the U.S. is 51. New labels add the option of starting treatment in women under 60 or within 10 years of menopause.
• In October 2026, the American College of Physicians (ACP) named hormone therapy the first-line treatment for hot flashes, and the American College of Obstetricians and Gynecologists (ACOG) strongly recommended it for women without contraindications.
• The change applies to FDA-approved products. Compounded (custom-mixed) hormones are not FDA-approved, and the change does not make them so.

The HRT label change at a glance (as of October 2026)

What Is a Black Box Warning, and Why Did HRT Have One?

A boxed warning, informally called a “black box” warning, is printed inside a black border at the top of a drug’s prescribing information. A review in American Family Physician describes it as “the most serious type of warning mandated by” the FDA. A boxed warning does not ban a drug: physicians can still use professional judgment to prescribe one. It does make many patients and prescribers hesitate, which is why the hormone therapy black box warning shaped menopause care for more than two decades.

The FDA approved its first hormone product for menopausal symptoms in 1942. The warning arrived much later, and it came from the Women’s Health Initiative. According to the FDA, the WHI estrogen-plus-progestin trial was stopped in 2002 after an increase in breast cancer. The estrogen-alone trial was stopped in 2004 because of more strokes and no evidence that it prevented heart disease. Two further WHI studies in women aged 65 to 79 reported more probable dementia. Starting in 2003, the FDA approved class-wide labeling that put a boxed warning on every MHT product, from pills and patches to low-dose vaginal creams.

The key detail is who was studied. According to the FDA, the average WHI participant was 63, about 12 years past the average U.S. menopause age of 51. That is older than many women who seek treatment for hot flashes around the menopause transition.

FDA Removes Black Box Warning on HRT: What Came Off the Label

Heart disease, breast cancer and dementia language

For all menopausal hormone therapies, this language is out of the box, and the probable dementia warning is out of the labeling entirely. For systemic products, the FDA told manufacturers to keep the cardiovascular and breast cancer warnings in the body of the label.

The end of “lowest dose for the shortest time”

The old box told prescribers to use the lowest effective dose for the shortest duration. That line is gone from the boxed warning. In a JAMA Viewpoint written by FDA leaders, including Commissioner Martin Makary, the authors state that “treatment decisions are individualized and fall within the clinical judgment of a clinician in discussion with a patient.” The label no longer sets a default “shortest time” rule, but that does not mean “more is better.”

New timing language: under 60 or within 10 years of menopause

Updated labels for systemic products now include a line on timing. On the 2026 label for one estradiol gel, it reads: “Consider initiating Divigel in women <60 years old or <10 years since menopause onset.” Labels for systemic products also add WHI data for women aged 50 to 59. If you are wondering whether this timing applies to you, a medically supervised HRT evaluation starts with your history, an exam and lab work, not with a prescription.

What Stayed: The Estrogen Black Box Warning for Endometrial Cancer

One boxed warning remains for systemic estrogen-alone products. On the updated Divigel label on DailyMed (revised February 2026), the old multi-risk box has been replaced with a single heading:

“WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS”

The first line under it reads: “There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.” The label’s “Recent Major Changes” section records that the boxed warnings for cardiovascular disorders, breast cancer and probable dementia were removed in February 2026.

“Unopposed” means estrogen taken without a progestogen (progesterone or a synthetic version of it). The National Cancer Institute notes that estrogen alone is linked to an increased risk of endometrial cancer in people with an intact uterus. That is why women who still have a uterus are generally prescribed a progestogen alongside systemic estrogen, and why estrogen alone is usually reserved for women who have had a hysterectomy. Under ACOG’s October 2026 guideline, persistent, unscheduled bleeding after starting hormone therapy warrants evaluation for endometrial changes, including cancer.

Black Box Warning Removal in 2026: Which HRT Labels Have Changed So Far

The FDA black box warning removal for HRT in 2026 is happening product by product, not all at once. Each manufacturer must submit new labeling, and the FDA must approve it. The FDA’s updated prescribing information page is the agency’s official list. As of October 2026, it names six products, and it was last updated on February 12, 2026. The FDA called these six a “first batch.” We found no announcement of a second batch at the time of writing.

This table explains which labels the FDA has updated. It is not a list of recommended products. If your product is not on the list, its label may still show the old wording, even though the FDA has asked for the change. To check, ask your pharmacist or prescriber, or look up your product’s current label on DailyMed, the National Library of Medicine’s label database.

Why the FDA Changed Course: The WHI Numbers, Re-Read by Age

The original WHI results were reported as relative risks across women aged 50 to 79. When the data are split by age, the picture changes. A 13-year follow-up published in JAMA in 2013 covered 27,347 women. It used a “global index,” a combined count of the major health events the WHI tracked, to compare treatment with placebo:

Other figures from the same paper:

• Combined therapy and breast cancer: invasive breast cancer was higher with CEE + MPA during the intervention phase (206 vs. 155 cases; hazard ratio 1.24).
• Estrogen alone and breast cancer: over cumulative follow-up, breast cancer was lower with CEE alone (hazard ratio 0.79).
• Heart disease: there was no statistically significant difference in coronary heart disease in either trial (hazard ratio 1.18 for CEE + MPA, 0.94 for CEE alone).

The FDA authors of the JAMA Viewpoint describe the WHI breast cancer finding as “1 additional nonfatal breast cancer diagnosis per 1000 women treated in a year.” They attribute it to the particular progestin formulation used in the study. Over the long term, an 18-year WHI mortality analysis found all-cause mortality of 27.1% with hormone therapy and 27.6% with placebo, which is no meaningful difference. The FDA also points to possible underuse: about 41 million U.S. women were aged 45 to 64 in 2020, roughly 34% of women aged 45 to 65 have moderate-to-severe hot flashes, and only about 2 million women aged 46 to 65 received a systemic MHT prescription that year.

For balance, the 2013 WHI authors concluded that the findings “do not support use of this therapy for chronic disease prevention,” although “it is appropriate for symptom management in some women.”

Not Everyone Agrees With the Change

The change has critics, and their published objections are worth knowing. JAMA published several comments on the FDA Viewpoint:

• Jacques Rossouw, MD, argued that the trials provided “definitive evidence that oral MHT should not be used for CVD prevention.” He wrote that the evidence still supports the lowest dose for the shortest time needed to treat hot flashes in younger women.
• Adriane Fugh-Berman, MD, and Judy Butler, MS, called the Viewpoint’s references “inadequate and miscited.” They argued that randomized trials contradict the cited heart and brain benefits and that cancer risks were understated.
• Wulf Utian, MD, PhD, took the opposite view. He called the removal “decades late in coming and inadequate in response.”

The Menopause Society took a middle position. It agreed with removing the boxed warning on low-dose vaginal estrogen, but cautioned that “systemic estrogen still comes with potential risks in certain individuals.” It also said clinicians should review medical conditions, personal and family history, symptoms and preferences before prescribing. Whichever side you find more convincing, the conclusion is the same: the label changed, but you still need an individual risk conversation.

Is HRT Safe Now? What the Label Change Does and Doesn’t Mean

“Is HRT safe?” has no single yes-or-no answer, before or after the label change. A smaller boxed warning means the FDA now considers the old warning overstated for many women. It does not mean hormone therapy is risk-free. The 2022 hormone therapy position statement of The Menopause Society (then the North American Menopause Society) found that for women younger than 60 or within 10 years of menopause onset, “the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss.” VMS, or vasomotor symptoms, means hot flashes and night sweats.

FDA approval also has limits. According to the FDA, menopausal hormone therapies are approved to treat moderate-to-severe hot flashes and night sweats and the vaginal and urinary symptoms of low estrogen, known as genitourinary syndrome of menopause (GSM). Some products are also approved to help prevent bone loss. The label change does not approve HRT for weight loss, anti-aging, or preventing heart disease or dementia, and no one should use it for those purposes. Hormone therapy is a prescription treatment that requires a medical evaluation, a diagnosis and ongoing supervision. It is not something to start, stop or adjust on your own.

HRT after 60 or more than 10 years after menopause

For women who start HRT after 60, or more than 10 years after menopause, the balance is less favorable. The same position statement cites greater absolute risks of coronary heart disease, stroke, venous thromboembolism (blood clots) and dementia in this group. The WHI age table above shows the same pattern. This is a reason for careful individual assessment, not an automatic “no.” The statement also notes that HRT “does not need to be routinely discontinued in women aged older than 60 or 65 years” when there is a documented reason to continue and it is reassessed regularly.

HRT Risks That Still Apply in 2026

HRT breast cancer risk

The NCI fact sheet reports that prior use of estrogen plus progestin is linked to an increased risk of breast cancer “for at least a decade after use is discontinued,” as well as an increased risk of death from lung cancer. Systemic estrogen alone was associated with a lower breast cancer risk in the WHI. Overall, the NCI states that MHT “is not associated with an increased risk of death from all causes.” Breast cancer risk depends on the regimen, so your prescriber should discuss the specific combination you are offered.

HRT and heart disease, stroke and blood clots

Updated systemic labels still carry a “Cardiovascular Disorders” warning. Absolute risk rises with age and with years since menopause. The Menopause Society’s 2022 statement notes that transdermal routes (through the skin) and lower doses may lower the risk of blood clots. Which route and dose suit you is a clinical decision, not a general rule to apply on your own.

Endometrial cancer

As covered above, this is the one risk that keeps its own boxed warning on systemic estrogen-alone products.

Who usually shouldn’t use systemic estrogen

Each product’s label lists its own contraindications (conditions that rule a medicine out). The 2026 Divigel label, as one example, lists:

• Abnormal genital bleeding of unknown cause
• Current or past breast cancer
• Estrogen-dependent cancers
• Active or past deep vein thrombosis (DVT) or pulmonary embolism (PE)
• Active or past arterial blood-clot disease, such as stroke or heart attack
• Liver impairment or disease
• Protein C, protein S or antithrombin deficiency, or another inherited clotting disorder
• A known severe allergic reaction to the product

Breast cancer survivors with bothersome symptoms should make treatment decisions with their oncology team, not with a general hormone prescriber alone.

Common side effects: on the same label, the most common adverse reactions (reported in more than 5% of users and more often than with placebo) were irregular vaginal bleeding, breast tenderness, vaginal yeast infection, nasal and throat inflammation, and upper respiratory infection. Side effects vary by product, dose and route. This article is general information, not individual medical advice; please read our medical disclaimers.

What the October 2026 Guidelines Say

Two major guidelines came out in October 2026, after most coverage of the label change was written. On October 5, the American College of Physicians published its recommendations in Annals of Internal Medicine. ACOG’s guideline, “Management of menopause-related vasomotor, sleep, and mood symptoms,” was reported by Healio on October 15.

ACOG also recommends physical exercise, cognitive behavioral therapy, acupuncture, mindfulness-based interventions and clinical hypnosis for one or more menopausal symptoms. These are generally meant to be combined with medication, although they can also be used on their own. ACOG found that current evidence does not support phytoestrogens, such as soy isoflavones, or herbal supplements for menopausal symptoms. If movement is part of your plan, our article on exercise for weight loss covers the basics. Many women also notice weight changes around menopause; we explain how hormones affect weight loss in a separate guide.

Does the Label Change Apply to Compounded or “Bioidentical” Hormones?

No. The FDA’s request and approvals apply to FDA-approved menopausal hormone therapy products. They do not apply to compounded hormone preparations, which pharmacies mix for individual patients and which have never gone through FDA approval.

“Bioidentical” describes a hormone with the same molecular structure as the hormones the body makes. It does not mean “compounded” or “safer.” Some FDA-approved products contain bioidentical hormones. According to a 2020 report from the National Academies of Sciences, Engineering, and Medicine, Bijuva is the only FDA-approved fixed-dose combination of bioidentical estradiol and progesterone.

The same report found that compounded preparations “are not required to demonstrate safety and effectiveness in clinical trials before being dispensed.” It concluded that they “are not adequately labeled” and often lack the boxed warnings, warnings and contraindications that FDA-approved products with the same ingredients carry. In one potency study it cited, compounded estradiol capsules ranged from 26% below to 5% above their labeled strength, and progesterone capsules from 9% below to 31% above. FDA-approved products typically must stay within about 10% of their label. The Menopause Society’s 2022 statement likewise lists “minimal government regulation and monitoring” among its safety concerns about compounded bioidentical hormones.

Vaginal Estrogen vs. Systemic HRT After the Label Change

Low-dose vaginal estrogen works mainly on local tissue and is used for GSM symptoms such as vaginal dryness, pain with intercourse and some urinary symptoms. Systemic HRT (pills, patches, gels and sprays) circulates throughout the body. For local vaginal products, the FDA asked companies to condense safety information to what is relevant to vaginal use. Estring, a vaginal estrogen ring, was among the first six updated labels.

As noted above, The Menopause Society supported this part of the change, saying the old warning may have deterred use of a treatment it describes as effective. Its 2022 statement adds that low-dose vaginal estrogen appears safe for select breast and endometrial cancer survivors whose symptoms don’t respond to non-hormonal therapy. That decision belongs with their oncology team. Vaginal estrogen is still a prescription, and new or persistent symptoms still need an evaluation.

When to Call a Clinician Right Away

Whatever type of hormone therapy you use, some symptoms need prompt attention. The CDC lists increased estrogen levels among the factors that raise the risk of blood clots.

• Signs of a blood clot in a leg or arm (DVT): swelling, pain or tenderness, warmth, or redness or discoloration. The CDC advises seeing your doctor as soon as possible.
• Signs of a blood clot in the lung (PE): difficulty breathing, a faster-than-normal or irregular heartbeat, chest pain that worsens with a deep breath or cough, coughing up blood, or lightheadedness or fainting. The CDC advises getting medical help immediately; for sudden trouble breathing or chest pain, call 911.
• Possible stroke or heart attack symptoms: call 911. Do not wait for a clinic appointment.
• Persistent or unscheduled vaginal bleeding after starting hormone therapy: contact your prescriber promptly for an evaluation, as ACOG recommends.
• A new breast lump or breast change: book a prompt evaluation with your clinician.

Before Your HRT Conversation: A 7-Point Checklist

This checklist reflects how our clinicians approach a conversation about HRT after the label change. Use it to prepare, not to diagnose yourself. Bring your answers to a licensed clinician.

1. FDA-approved or compounded? Check the pharmacy label. The 2026 label change covers FDA-approved products only.
2. Systemic or vaginal? Pills, patches, gels and sprays are systemic. Low-dose rings, creams and tablets used in the vagina are local, and their risk information is different.
3. Do you still have a uterus? If so, systemic estrogen is generally paired with a progestogen to protect the uterine lining.
4. How old are you, and how long ago was your last period? Under 60 or within 10 years of menopause is the window the new labels and guidelines describe.
5. Personal and family history: breast cancer, blood clots, stroke, heart attack, liver disease, clotting disorders or unexplained bleeding. These match the label contraindications.
6. Your main symptom and its impact: how often hot flashes or night sweats happen, and how much they affect sleep, work or mood.
7. Questions to ask: What does my product’s current label say? Which route makes sense for my risk profile? How often will we reassess the plan?

If you’d like to go through these points with a clinician, here is how getting started at our clinic works.

Reviewing Hormone Therapy After the Label Change at Cardiomender Weight Loss & Aesthetics

Cardiomender Weight Loss & Aesthetics has offered in-person care at one clinic, 17009 Pines Blvd in Pembroke Pines, since 2009. For women’s hormone therapy, the process starts with a review of your medical history and symptoms, a physical exam to check for contraindications, and blood tests to help confirm whether HRT is clinically appropriate. A treatment plan comes only after that, and regular follow-up visits track how it is working. Our care approach and our clinical team are focused on supervision rather than one-time prescriptions.

Many women who come to us about menopause symptoms are also dealing with midlife weight changes. Our team also runs medical weight loss in Pembroke Pines with nutrition guidance, and we’ve written about which hormones affect weight. Patients travel to our single Pembroke Pines clinic from across South Florida, including those looking for HRT for women in Fort Lauderdale, Miami, Boca Raton and Coral Gables. You can read more about Cardiomender or check our clinic hours before you visit.

HRT Black Box Warning: Frequently Asked Questions

Why did HRT have a black box warning in the first place?

The WHI trials were stopped early, in 2002 (estrogen plus progestin, due to more breast cancer) and in 2004 (estrogen alone, due to more strokes). Starting in 2003, the FDA put a class-wide boxed warning on all menopausal hormone products. The trial participants averaged 63 years old, older than most women who start HRT for symptoms.

Was the black box warning removed from HRT completely?

No. The boxed warning was removed from HRT for cardiovascular disease, breast cancer and probable dementia, but the endometrial cancer boxed warning stays for systemic estrogen-alone products. Cardiovascular and breast cancer risks remain in the Warnings and Precautions section of systemic labels.

Does the label change apply to the HRT I already take?

The FDA has asked for the change across all FDA-approved menopausal hormone products. As of October 2026, though, only six products appear on the FDA’s updated-labels page. Ask your pharmacist or prescriber whether your product’s label has been updated. Do not change or stop a prescription on your own.

Is HRT considered a carcinogen?

The answer depends on the regimen. The National Cancer Institute reports that estrogen plus progestin is linked to increased breast cancer risk, and estrogen alone to increased endometrial cancer risk in women with a uterus. Systemic estrogen alone is linked to lower breast cancer risk, and MHT overall is not associated with increased all-cause death.

Is it healthier not to take HRT?

For women without bothersome symptoms, there is no reason to start: the WHI authors concluded that hormone therapy should not be used for chronic disease prevention. For women with moderate-to-severe hot flashes and no contraindications, ACP now recommends hormone therapy as the first-line option, and ACOG strongly recommends it. The right choice depends on your symptoms and your risk profile.

Why have some doctors been hesitant to prescribe HRT?

After 2002, the WHI results and the boxed warning made many clinicians cautious. The FDA notes that only about 2 million women aged 46 to 65 received a systemic MHT prescription in 2020, while about 41 million U.S. women were aged 45 to 64, which suggests possible underuse. Some experts still argue for caution, so expect your clinician to weigh your history carefully.

Can I start HRT after 60?

Possibly, but the benefit-risk balance is less favorable. The Menopause Society’s 2022 statement cites greater absolute risks of heart disease, stroke, blood clots and dementia for women who start after 60 or more than 10 years past menopause. This decision needs an individual evaluation.

Does the change make compounded bioidentical hormones FDA-approved?

No. Compounded preparations are not FDA-approved and are not covered by the label change. The National Academies found that they are not adequately labeled and that their potency can vary from the label.

If the label change has raised questions about your own hormone therapy, the next step is a conversation with a licensed clinician who knows your history. Cardiomender Weight Loss & Aesthetics serves patients across South Florida at our Pembroke Pines clinic. Call (954) 799-6439 or request a consultation to review your symptoms, your current prescription and your options with our medical team.